Literature DB >> 26903513

Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination.

Richard Golnik1, Andrea Lehmann1, Peter-Michael Kloetzel1, Frédéric Ebstein2.   

Abstract

The supply of MHC class I-restricted peptides is primarily ensured by the degradation of intracellular proteins via the ubiquitin-proteasome system. Depending on the target and the enzymes involved, ubiquitination is a process that may dramatically vary in terms of linkages, length, and attachment sites. Here we identified the unique lysine residue at position 124 of the NY-ESO-1 cancer/testis antigen as the acceptor site for the formation of canonical Lys-48-linkages. Interestingly, a lysine-less form of NY-ESO-1 was as efficient as its wild-type counterpart in supplying the HLA-A*0201-restricted NY-ESO-1157-165 antigenic peptide. In fact, we show that the regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites. In summary, our data underscore the significance of atypical ubiquitination in the modulation of MHC class I antigen processing.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  antigen processing; proteasome; protein degradation; tumor immunology; ubiquitin

Mesh:

Substances:

Year:  2016        PMID: 26903513      PMCID: PMC4861448          DOI: 10.1074/jbc.M115.705178

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress.

Authors:  Ulrike Seifert; Lukasz P Bialy; Frédéric Ebstein; Dawadschargal Bech-Otschir; Antje Voigt; Friederike Schröter; Timour Prozorovski; Nicole Lange; Janos Steffen; Melanie Rieger; Ulrike Kuckelkorn; Orhan Aktas; Peter-M Kloetzel; Elke Krüger
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

Review 2.  The complexity of recognition of ubiquitinated substrates by the 26S proteasome.

Authors:  Aaron Ciechanover; Ariel Stanhill
Journal:  Biochim Biophys Acta       Date:  2013-07-18

3.  Reversible 26S proteasome disassembly upon mitochondrial stress.

Authors:  Nurit Livnat-Levanon; Éva Kevei; Oded Kleifeld; Daria Krutauz; Alexandra Segref; Teresa Rinaldi; Zoi Erpapazoglou; Mickael Cohen; Noa Reis; Thorsten Hoppe; Michael H Glickman
Journal:  Cell Rep       Date:  2014-05-22       Impact factor: 9.423

Review 4.  Re-examining class-I presentation and the DRiP hypothesis.

Authors:  Kenneth L Rock; Diego J Farfán-Arribas; Jeff D Colbert; Alfred L Goldberg
Journal:  Trends Immunol       Date:  2014-02-21       Impact factor: 16.687

Review 5.  Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands.

Authors:  Brian P Dolan; Jack R Bennink; Jonathan W Yewdell
Journal:  Cell Mol Life Sci       Date:  2011-03-17       Impact factor: 9.261

6.  Diverse polyubiquitin chains accumulate following 26S proteasomal dysfunction in mammalian neurones.

Authors:  Lynn Bedford; Robert Layfield; R John Mayer; Junmin Peng; Ping Xu
Journal:  Neurosci Lett       Date:  2011-01-05       Impact factor: 3.046

Review 7.  The ubiquitin code.

Authors:  David Komander; Michael Rape
Journal:  Annu Rev Biochem       Date:  2012-04-10       Impact factor: 23.643

8.  Autoubiquitination of the 26S proteasome on Rpn13 regulates breakdown of ubiquitin conjugates.

Authors:  Henrike C Besche; Zhe Sha; Nikolay V Kukushkin; Andreas Peth; Eva-Maria Hock; Woong Kim; Steven Gygi; Juan A Gutierrez; Hua Liao; Lawrence Dick; Alfred L Goldberg
Journal:  EMBO J       Date:  2014-05-08       Impact factor: 11.598

Review 9.  The role of the proteasome in the generation of MHC class I ligands and immune responses.

Authors:  E J A M Sijts; P M Kloetzel
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

10.  The FAT10- and ubiquitin-dependent degradation machineries exhibit common and distinct requirements for MHC class I antigen presentation.

Authors:  Frédéric Ebstein; Andrea Lehmann; Peter-Michael Kloetzel
Journal:  Cell Mol Life Sci       Date:  2012-02-19       Impact factor: 9.261

View more
  10 in total

1.  Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.

Authors:  Jiajie Wei; Damien Zanker; Anthony R Di Carluccio; Margery G Smelkinson; Kazuyo Takeda; Mina O Seedhom; Devin Dersh; James S Gibbs; Ning Yang; Ajit Jadhav; Weisan Chen; Jonathan W Yewdell
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

2.  A Cycle of Ubiquitination Regulates Adaptor Function of the Nedd4-Family Ubiquitin Ligase Rsp5.

Authors:  Chris MacDonald; S Brookhart Shields; Charlotte A Williams; Stanley Winistorfer; Robert C Piper
Journal:  Curr Biol       Date:  2020-01-16       Impact factor: 10.834

Review 3.  Bacterial virulence mediated by orthogonal post-translational modification.

Authors:  Kaitlin A Chambers; Rebecca A Scheck
Journal:  Nat Chem Biol       Date:  2020-09-17       Impact factor: 15.040

Review 4.  Cellular functions and molecular mechanisms of non-lysine ubiquitination.

Authors:  Amie J McClellan; Sophie Heiden Laugesen; Lars Ellgaard
Journal:  Open Biol       Date:  2019-09-18       Impact factor: 6.411

Review 5.  The Ubiquitin-Proteasome System in Immune Cells.

Authors:  Gonca Çetin; Sandro Klafack; Maja Studencka-Turski; Elke Krüger; Frédéric Ebstein
Journal:  Biomolecules       Date:  2021-01-05

6.  Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.

Authors:  Hai Cai; Hang Chen; Qi Huang; Jun-Ming Zhu; Zhi-Bin Ke; Yun-Zhi Lin; Qing-Shui Zheng; Yong Wei; Ning Xu; Xue-Yi Xue
Journal:  Pathol Oncol Res       Date:  2021-10-29       Impact factor: 3.201

7.  Isopeptide and ester bond ubiquitination both regulate degradation of the human dopamine receptor 4.

Authors:  Jennifer C Peeler; Sophia Schedin-Weiss; Mariluz Soula; Manija A Kazmi; Thomas P Sakmar
Journal:  J Biol Chem       Date:  2017-11-03       Impact factor: 5.157

8.  RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.

Authors:  Ruey-Shyang Soong; Ravi K Anchoori; Benjamin Yang; Andrew Yang; Ssu-Hsueh Tseng; Liangmei He; Ya-Chea Tsai; Richard B S Roden; Chien-Fu Hung
Journal:  Oncotarget       Date:  2016-10-18

9.  Engineering anti-cancer nanovaccine based on antigen cross-presentation.

Authors:  Vaishnavi U Warrier; Amina I Makandar; Manoj Garg; Gautam Sethi; Ravi Kant; Jayanta K Pal; Eiji Yuba; Rajesh Kumar Gupta
Journal:  Biosci Rep       Date:  2019-10-30       Impact factor: 3.840

10.  Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors.

Authors:  Ravi K Anchoori; Logan George; Ssu-Hsueh Tseng; Brandon Lam; Srinidhi Polkampally; Anjali D Amiano; Palmer Foran; Hannah Tsingine; Harideep Samanapally; Fernanda Carrizo Velasquez; Samarjit Das; Deyin Xing; Ahmad Bin Salam; Balasubramanyam Karanam; Chien-Fu Hung; Richard B S Roden
Journal:  PLoS One       Date:  2021-09-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.